Accurate, real-time monitoring has seen the technology gain UK NICE approval and recognition as one of six so-called "High Impact Innovations" in an NHS report.

Until recently the need to insert an in-dwelling a probe into the oesophagus has limited ODM's use to anaesthetised or critically ill patients. Recognising that hospitals would benefit from a single platform across all their monitoring needs, Deltex has been adding new modalities that include minimally invasive options. In so doing the company has embarked on a strategic change of direction that will increase its utility across hospital monitoring needs.

Deltex’s oesophageal doppler monitoring (ODM) system is supplemented by pulse-pressure wave analysis (PPWA), which provides Doppler-derived continuous monitoring in postoperative and medical patients in critical care.

It also features high definition impedance cardiography (HD-ICG), which offers a non-invasive method of deriving cardiac output. This increases the system’s utility to include obstetrics, emergency medicine and even ward care

Now Deltex is introducing Velocity/Pressure (VP) Loops, which charts these two vital parameters and yields graphical representation through each and every heartbeat, 180 times a second. The result delivers clinicians the ability to assess the patient’s haemodynamic status in real time and closely monitor the impact of therapeutic interventions.

Deltex believes that this combination is the ultimate diagnostic tool to visually guide haemodynamic management in anaesthetic care. These sequential additions to the ODM system’s capabilities have reached a point where it needs a new name. This collection of best-in-class haemodynamic monitoring modes offers anaesthetic specialists an unparalleled insight into the patient’s fluid status, so continuing the theme, it's called TrueVue.

On the VP Loops capability, Dr. Fabrice Vallée of Hôpital Lariboisière, Paris stated: “I’ve never before been able to view my patient’s haemodynamic status as well as this. It’s an eye-opening experience to have such beat by beat visibility of monitoring and the ability to see and track my interventions so accurately. I have no doubt that adoption of this technology will lead to improved outcomes and fewer post-operative complications as we can now optimise haemodynamics in real time.”

Deltex's managing director Andy Mears stated: "Clinical outcome papers support oesophageal Doppler with a wealth of evidence. Its use can significantly reduce complications such as acute kidney injury. However, despite our confidence in the technology’s power, it's not, until now, been a universal system, simply because an in-dwelling oesophageal probe is not tolerated in the awake patient. So we've been integrating other best-in-class monitoring modes, which means we can now claim to have a system that works across all hospital monitoring needs. And now, by adding the VP Loops capability the system offers clinicians the clearest view of patients’ fluid status they’ve ever had."

Mears concluded: “The system is so significantly enhanced compared with even a year ago, that we want to shout about it from the rooftops. This has started with a new name that speaks of the eye-opening ability to actually see what’s going on with the patient’s fluid levels. TrueVue does that.”